Other meanings of GLP-1 receptor agonist
MEDICINE · METABOLIC HEALTH
A GLP-1 receptor agonist is a class of drugs used for type 2 diabetes and obesity. These medicines mimic glucagon-like peptide-1, a gut hormone that enhances glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite. Their effects can improve blood-glucose control and produce clinically meaningful weight loss, while some agents also lower cardiovascular risk in selected people with diabetes or obesity.
GLP-1 receptor agonists lower blood glucose while influencing appetite and digestion. By activating GLP-1 receptors in the pancreas, they stimulate insulin secretion when glucose is elevated and reduce glucagon secretion; this glucose dependence means they generally cause less hypoglycemia than insulin or sulfonylureas when used alone. They also slow gastric emptying and act on brain pathways involved in satiety.
Clinicians prescribe these drugs mainly for type 2 diabetes and chronic weight management in eligible people with obesity or overweight plus a related condition. Common members include exenatide, liraglutide, dulaglutide, lixisenatide, and semaglutide. Formulations differ in dose, frequency, approved indications, and cardiovascular evidence.
GLP-1 receptor agonists can improve hemoglobin A1c and reduce body weight, although the magnitude varies substantially among agents and treatment doses. In obesity trials, daily liraglutide and weekly semaglutide produced greater average weight loss than placebo alongside lifestyle intervention.12
Several outcome trials have shown cardiovascular benefit in particular populations rather than as a universal class effect. Liraglutide reduced major cardiovascular events in adults with type 2 diabetes at high cardiovascular risk, while semaglutide reduced events in a large trial of people with overweight or obesity and established cardiovascular disease, even without diabetes.34 Treatment decisions still depend on comorbidities, tolerability, cost, and access.
Most GLP-1 receptor agonists are injected under the skin, with schedules ranging from twice daily to once weekly; oral semaglutide is an exception. Doses are usually increased gradually to limit gastrointestinal effects. Nausea, vomiting, diarrhea, constipation, and reduced appetite are the most frequent adverse effects, and they often lessen as the body adapts.
Dehydration from severe gastrointestinal symptoms can contribute to kidney injury, while gallbladder disease and pancreatitis are uncommon but clinically important concerns. Hypoglycemia becomes more likely when a GLP-1 receptor agonist is combined with insulin or a sulfonylurea. These medicines are not substitutes for insulin in type 1 diabetes or diabetic ketoacidosis. Product labeling and clinical assessment guide use in pregnancy, severe gastrointestinal disease, and people with relevant thyroid-cancer risks.
GLP-1 receptor agonists are not interchangeable, and the term does not include every modern drug marketed for weight or glucose control. Tirzepatide, for example, activates both the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, making it a dual agonist rather than a selective GLP-1 receptor agonist.
The class originated partly from research on exendin-4, a peptide identified in the venom of the Gila monster, which helped lead to exenatide. Longer-acting medicines maintain receptor stimulation over days or weeks, whereas short-acting agents have stronger effects on post-meal glucose and gastric emptying. Weight commonly returns after discontinuation, reflecting the chronic biology of appetite regulation rather than simple treatment failure. Cardiovascular and kidney findings are therefore considered alongside glucose and weight outcomes.
Individual response is heterogeneous: some patients experience substantial weight loss, while others stop treatment because gastrointestinal effects or cost outweigh perceived benefit. Rapid dose escalation, large meals, and concurrent medicines that slow digestion can worsen symptoms. Delayed gastric emptying may also affect the absorption of certain oral medicines, an issue requiring medication-specific advice.
Research has expanded beyond glucose and weight to examine heart failure, chronic kidney disease, liver disease, and neurodegenerative conditions, but evidence and regulatory approvals differ by drug and indication. The strongest established evidence remains for type 2 diabetes, obesity treatment, and selected cardiovascular risk reduction. Compounded or counterfeit products present additional quality and dosing risks and should not be treated as equivalent to approved formulations.
Approved indications, contraindications, and formulations vary by country and product; prescribing information and individualized medical advice govern treatment.
Help improve the encyclopedia. Reports go straight to the site manager.